bifeprunox, olanzapine — Competitive Intelligence Brief

bifeprunox, olanzapine (bifeprunox, olanzapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic D2 receptor, 5-HT2A receptor Psychiatry Small molecule

Target snapshot

bifeprunox, olanzapine (bifeprunox, olanzapine) — Wyeth is now a wholly owned subsidiary of Pfizer. Bifeprunox is a selective dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, and olanzapine is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bifeprunox, olanzapine TARGET	bifeprunox, olanzapine	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Atypical antipsychotic	D2 receptor, 5-HT2A receptor
Rapid Acting Intramuscular Olanzapine	Rapid Acting Intramuscular Olanzapine	Eli Lilly and Company	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Zyprexa® (OLANZapine 5MG)	Zyprexa® (OLANZapine 5MG)	CR-CSSS Champlain-Charles-Le Moyne	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Olanzapine, risperidone	Olanzapine, risperidone	AstraZeneca	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperidone and placebo comparator	Risperidone and placebo comparator	University of Alabama at Birmingham	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperidone, oral tablets	Risperidone, oral tablets	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperdal Consta (drug)	Risperdal Consta (drug)	University of Illinois at Chicago	phase 3	Atypical antipsychotic	D2 receptor, 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

1. Shanghai Mental Health Center · 10 drugs in this class
2. AstraZeneca · 6 drugs in this class
3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
5. Eli Lilly and Company · 4 drugs in this class
6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
7. Medical University of Vienna · 2 drugs in this class
8. Organon and Co · 2 drugs in this class
9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
10. H. Lundbeck A/S · 2 drugs in this class